Onconetix (NASDAQ:ONCO) Stock Gets Downgrade from Wall Street Zen

Onconetix (NASDAQ:ONCO – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings lowered shares of Onconetix from a “sell (e+)” rating to a “sell (e)” rating in a research note on Tuesday. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Check Out Our Latest Report on Onconetix

Onconetix Stock Down 8.5%

NASDAQ ONCO opened at $2.89 on Friday. Onconetix has a 1 year low of $2.76 and a 1 year high of $1,610.00. The business’s fifty day moving average is $5.70 and its two-hundred day moving average is $92.05.

About Onconetix

(Get Free Report)

Onconetix, Inc. is a biotechnology company focused on cancer-related diagnostics and therapeutics, with an emphasis on prostate health. Its portfolio includes Proclarix, a blood-based diagnostic test developed to help assess prostate cancer risk. Proclarix was developed by Swiss company Proteomedix, which Onconetix acquired in 2023. The test has received a CE mark for use in Europe; its availability and regulatory status may differ in other markets. Onconetix was formerly known as Blue Water Biotech before adopting its current name in 2024.

Recommended Stories

Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.